Ann Lab Med.  2015 Sep;35(5):523-530. 10.3343/alm.2015.35.5.523.

In Vitro Activity of Tedizolid Against Gram-Positive Bacteria in Patients With Skin and Skin Structure Infections and Hospital-Acquired Pneumonia: A Korean Multicenter Study

• Lee Y
• Hong SK
• Choi S
• Im W
• Yong D
• Lee K

• KMID: 2369769
• DOI: http://doi.org/10.3343/alm.2015.35.5.523

Abstract

We compared the activities of tedizolid to those of linezolid and other commonly used antimicrobial agents against gram-positive cocci recovered from patients with skin and skin structure infections (SSSIs) and hospital-acquired pneumonia (HAP) in Korean hospitals. Gram-positive isolates were collected from 356 patients with SSSIs and 144 patients with HAP at eight hospitals in Korea from 2011 to 2014. SSSIs included impetigo, cellulitis, erysipelas, furuncles, abscesses, and infected burns. Antimicrobial susceptibility was tested by using the CLSI agar dilution method. All of the gram-positive isolates were inhibited by < or =1 microg/mL tedizolid. The minimum inhibitory concentration [MIC]90 of tedizolid was 0.5 microg/mL for methicillin-resistant Staphylococcus aureus, which was 4-fold lower than that of linezolid. Tedizolid may become a useful option for the treatment of SSSIs and HAP caused by gram-positive bacteria.

Keyword

Tedizolid; Skin; Soft tissue; Infection; Pneumonia; Gram-positive bacteria

MeSH Terms

Abscess
Agar
Anti-Infective Agents
Burns
Cellulitis
Erysipelas
Furunculosis
Gram-Positive Bacteria*
Gram-Positive Cocci
Humans
Impetigo
Korea
Methicillin-Resistant Staphylococcus aureus
Microbial Sensitivity Tests
Pneumonia*
Skin*
Agar
Anti-Infective Agents

Reference

1. Rajan S. Skin and soft-tissue infections: classifying and treating a spectrum. Cleve Clin J Med. 2012; 79:57–66. PMID: 22219235.

2. Rubinstein E, Kollef MH, Nathwani D. Pneumonia caused by methicillin-resistant Staphylococcus aureus. Clin Infect Dis. 2008; 46(S5):S378–S385. PMID: 18462093.

3. Mendes RE, Flamm RK, Hogan PA, Ross JE, Jones RN. Summary of linezolid activity and resistance mechanisms detected during the 2012 LEADER surveillance program for the United States. Antimicrob Agents Chemother. 2014; 58:1243–1247. PMID: 24323470.

4. Gu B, Kelesidis T, Tsiodras S, Hindler J, Humphries RM. The emerging problem of linezolid-resistant Staphylococcus. J Antimicrob Chemother. 2013; 68:4–11. PMID: 22949625.

5. Moravvej Z, Estaji F, Askari E, Solhjou K, Naderi Nasab M, Saadat S. Update on the global number of vancomycin-resistant Staphylococcus aureus (VRSA) strains. Int J Antimicrob Agents. 2013; 42:370–371. PMID: 23880172.

6. Rodríguez-Avial I, Culebras E, Betriu C, Morales G, Pena I, Picazo JJ. In vitro activity of tedizolid (TR-700) against linezolid-resistant staphylococci. J Antimicrob Chemother. 2012; 67:167–169. PMID: 21954458.

7. Shaw KJ, Poppe S, Schaadt R, Brown-Driver V, Finn J, Pillar CM, et al. In vitro activity of TR-700, the antibacterial moiety of the prodrug TR-701, against linezolid-resistant strains. Antimicrob Agents Chemother. 2008; 52:4442–4447. PMID: 18838596.

8. Moellering RC Jr. Tedizolid: a novel oxazolidinone for Gram-positive infections. Clin Infect Dis. 2014; 58(S1):S1–S3. PMID: 24343826.

9. Kisgen JJ, Mansour H, Unger NR, Childs LM. Tedizolid: a new oxazolidinone antimicrobial. Am J Health Syst Pharm. 2014; 71:621–633. PMID: 24688035.

10. Yum JH, Choi SH, Yong D, Chong Y, Im WB, Rhee DK, et al. Comparative in vitro activities of torezolid (DA-7157) against clinical isolates of aerobic and anaerobic bacteria in South Korea. Antimicrob Agents Chemother. 2010; 54:5381–5386. PMID: 20837761.

11. US Food and Drug Administration. Guidance for industry: acute bacterial skin and skin structure infections: developing drugs for treatment. US Food and Drug Administration;2010.

12. Goldstein EJ, Solomkin JS, Citron DM, Alder JD. Clinical efficacy and correlation of clinical outcomes with in vitro susceptibility for anaerobic bacteria in patients with complicated intra-abdominal infections treated with moxifloxacin. Clin Infect Dis. 2011; 53:1074–1080. PMID: 21998288.

13. Brook I, Wexler HM, Goldstein EJ. Antianaerobic antimicrobials: spectrum and susceptibility testing. Clin Microbiol Rev. 2013; 26:526–546. PMID: 23824372.

14. Sivextro (tedizolid) Prescribing information. Lexington, MA: Cubist Pharmaceuticals;2014.

15. Thomson KS, Goering RV. Activity of tedizolid (TR-700) against well-characterized methicillin-resistant Staphylococcus aureus strains of diverse epidemiological origins. Antimicrob Agents Chemother. 2013; 57:2892–2895. PMID: 23571550.